Full Press Release Details
EyeGate is Now Kiora Pharmaceuticals; Provides
Sharpened Clinical Development Strategy
SALT LAKE CITY, UT, November 8, 2021 - Kiora Pharmaceuticals, Inc.
(NASDAQ: KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG).
Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects
the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential
to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company's newly revamped clinical
development strategy is available in the Investors section of the Company's new website at www.kiorapharma.com.
"The rebranding reflects our sharpened focus on developing novel
ophthalmic therapeutics," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "Our small molecule for
Retinitis Pigmentosa could offer a revolutionary treatment for a rare disease with a potentially expedited path to market. We'll
continue planned development of our mid and later stage clinical candidates in anterior segment eye diseases and explore partnering opportunities
of promising systemic indications outside our core focus."
Expanded Pipeline and Milestones
Kiora's pipeline now consists of three assets in early to late-stage
development for both common and rare eye diseases. The company anticipates achieving several milestones for these programs that will drive
value in the organization.
is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301
is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration.
KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH")
with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome
the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified
form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. For more information, please visit www.kiorapharma.com.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking"
and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking"
statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing
approval efforts pertaining to Kiora's products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such
approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that
may cause results to differ materially from the statements set forth in this press release, including, among other things, market and
other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report
on Form 10-K filed with the SEC on March 25, 2021 or described in Kiora's other public filings. Kiora's results
may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only
as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions
to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances
on which any such statement is based, except as required by law.